Uterine Cancer

Uterine sarcoma is a rare cancer that starts in the muscle (myometrium) or supporting tissues of the uterus (womb) — not in the inner lining (endometrium). It behaves like other softtissue sarcomas and is approached differently than endometrial carcinoma.

What makes uterine sarcoma different from other uterine cancers?

Origin: Sarcoma arises from muscle or stromal/connective tissue in the uterus, whereas endometrial carcinoma begins in the endometrial lining. Management, staging, and drug responsiveness differ.
Carcinosarcoma: Although it has features of both carcinoma and sarcoma, it is now classified and staged as an endometrial carcinoma, not a true sarcoma.

Main subtypes

Uterine leiomyosarcoma (LMS)

Develops from the uterine muscle; can grow and spread rapidly.

Endometrial stromal sarcoma (ESS)

Arises from the stromal/supporting tissue of the endometrium; low-grade ESS tends to grow slowly and is often hormonereceptor positive, while high-grade/undifferentiated forms are more aggressive.

Adenosarcoma

Mixed epithelial–stromal tumor that behaves as a sarcoma; treatment and prognosis differ from endometrial carcinoma.

(Uterine sarcoma is uncommon overall; patterns of spread and treatment choices mirror those for other softtissue sarcomas, adapted to the pelvic anatomy.)

Signs & Symptoms

Abnormal vaginal bleeding (including postmenopausal bleeding) is the most common symptom; others include pelvic/abdominal pain or fullness, urinary frequency, or a vaginal mass. These symptoms are not specific and warrant evaluation.

Risk factors

Prior pelvic radiation is a recognized risk.
Tamoxifen exposure (for breast cancer) increases risk; people taking tamoxifen should have regular pelvic exams and report any abnormal bleeding promptly.

Diagnosis

help identify a suspicious uterine mass.

(sometimes with hysteroscopy or D&C) is used to confirm histology; the final diagnosis and grade are established by pathology.

additional imaging (e.g., CT chest/abdomen/pelvis) is used for staging and surgical planning.

Staging

Uterine sarcoma is staged using FIGO/AJCC TNM systems specific to LMS and ESS. Staging incorporates:

Tumor extent (T)

size and whether the tumor extends beyond the uterus

Nodal status (N)

spread to pelvic/paraaortic nodes

Metastasis (M)

spread to distant organs (e.g., lungs, liver, bone)

Treatment options (by subtype and stage)

Surgery (foundation of care)

Radioactive iodine (RAI) may be recommended after surgery for selected DTC patients to ablate remnant tissue and reduce recurrence risk; not all patients benefit.

Radiation therapy

RETtargeted therapies and other systemic options may be used for advanced, unresectable, or metastatic MTC.

Chemotherapy

Molecular testing can identify actionable mutations for targeted treatment strategies.

Hormone therapy (especially for ESS):

Molecular testing can identify actionable mutations for targeted treatment strategies.

Targeted therapy & immunotherapy:

Molecular testing can identify actionale mutations for targeted treatment strategies.

Because uterine sarcoma is rare, many experts recommend clinicaltrial participation whenever available to access emerging therapies and contribute to better evidence. Current Clinical Trials – Illinois CancerCare

Prognosis

Outcomes vary by histology, stage, grade, and resectability. In general, lowgrade ESS has a more favorable outlook than LMS or undifferentiated sarcomas; survival statistics are commonly presented by SEER stage groups (localized/regional/distant). Your physician will interpret what published survival figures mean for your situation.

Follow-Up & Survivorship

Regular followup is important to detect and manage recurrence promptly (clinical exam, symptom review, and imaging tailored to subtype and prior stage).
Many people benefit from rehabilitation, sexual health and pelvic floor support, fertility counseling (as appropriate), and psychosocial resources typical for softtissue sarcomas.

Why Choose Illinois CancerCare

Multidisciplinary sarcoma expertise—coordinating gynecologic oncology, surgical oncology, medical oncology, radiation oncology, pathology, radiology, and genetics—to tailor staging, surgery, and systemic therapy to your subtype and goals.
Access to clinical trials and evidence aligned options (surgery, radiation, chemotherapy, hormone therapy for ESS, and novel systemic therapies for advanced disease).

Sources & Patient Friendly References

All information was taken from the NCI (National Cancer Institute) and ACS (American Cancer Society).